A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

Part of paid clinical trials in Los Alamitos, California.

Sponsor
Eli Lilly and Company
Study ID
NCT07152002
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy
  • Overweight or Obesity

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • LY4064912 — DRUG
    Administered SC
  • LY4064912 — DRUG
    Administered IV
  • Placebo — DRUG
    Administered SC
  • Placebo — DRUG
    Administered IV

Study Details

The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Key Dates

Start date
Aug 28, 2025
Status verified
Apr 2026
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
144 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Part A: LY4064912 (Cohorts 1-6)
    LY4064912 administered subcutaneously (SC)
  • Experimental: Part A: LY4064912 (Cohort 6a)
    LY4064912 administered intravenously (IV)
  • Placebo Comparator: Part A: Placebo
    Placebo administered SC and IV
  • Experimental: Part B: LY4064912 (Cohorts 7-10)
    LY4064912 administered SC
  • Placebo Comparator: Part B: Placebo
    Placebo administered SC
  • Experimental: Part C: LY4064912 (Cohort 11)
    LY4064912 administered SC
  • Experimental: Part C: Placebo
    Placebo administered SC

Primary Outcome Measure

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Postdose to Approximately Week 27 ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (2)

FacilityCityStateZIPSite coordinators
Collaborative Neuroscience Network - CNSLos AlamitosCalifornia90720
714-799-7799
Steven Reynolds (PRINCIPAL_INVESTIGATOR)
ICON Early Phase ServicesSan AntonioTexas78209
210-225-5437
Robert Bass (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Alamitos, CA

By research site
Collaborative Neuroscience Network - CNS· Los Alamitos, CAICON Early Phase Services· San Antonio, TX

Related Studies